854044-35-2

Upstream product

• 110-89-4 piperidine 
• 446-35-5 2,4-Difluoronitrobenzene 

Downstream Products

• 854044-36-3 dimethyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine 
• 854044-42-1 1-(2-nitro-5-pyrazol-1-yl-phenyl)-piperidine 
• 854044-43-2 N-Methyl-(4-nitro-3-piperidin-1-yl-phenyl)-amine 
• 353501-02-7 1-methyl-4-(4-nitro-3-(piperidin-1-yl)phenyl)piperazine 
• 202279-91-2 4-nitro-3-piperidin-1-yl-phenylamine 
• 885704-57-4 1-(5-azido-2-nitro-phenyl)-piperidine 
• 346704-04-9 1-[4-nitro-3-(piperidin-1-yl)phenyl]piperazine 
• 885704-59-6 1-[5-(4-methyl-pyrazol-1-yl)-2-nitro-phenyl]-piperidine 

Relevant academic research and scientific papers

KINASE INHIBITORS AND METHODS FOR MAKING AND USING

Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Ortho selectivity in SNAr substitutions of 2,4-dihaloaromatic compounds. Reactions with piperidine

A broad survey of aromatic compounds with halogens positioned both ortho and para to activating groups was studied in SNAr reactions with piperidine. Regioselectivities varied with the substituent group and the polarity of the solvent. Many act

AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE

The invention relates to compounds of Formula (I), wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.

C-fms kinase inhibitors

The invention is directed to compounds of Formulae I: wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.